Immutep Limited Share Price




Biotechnology & Medical Research

Market Closed - Australian S.E. 07:10:50 30/05/2024 BST 5-day change 1st Jan Change
0.44 AUD 0.00% Intraday chart for Immutep Limited -4.35% +27.54%


Sales 2024 * 3.55M 2.36M 185M Sales 2025 * 14.85M 9.86M 774M Capitalization 523M 347M 27.27B
Net income 2024 * -45M -29.88M -2.35B Net income 2025 * -44M -29.22M -2.29B EV / Sales 2024 * 126 x
Net cash position 2024 * 75.11M 49.88M 3.92B Net cash position 2025 * 61.67M 40.95M 3.22B EV / Sales 2025 * 31.1 x
P/E ratio 2024 *
-11.5 x
P/E ratio 2025 *
-12.2 x
Employees -
Yield 2024 *
Yield 2025 *
Free-Float 96.19%
More Fundamentals * Assessed data
Dynamic Chart
Capital One Initiates Immutep at Overweight Rating With $10 Price Target MT
Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data MT
Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024 CI
Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma CI
Immutep Validates Initial Efficacy of Immunotherapy Medication in Phase Two Cancer Trial MT
Immutep Limited Provides an Update on the Ongoing Development of its Product Candidates, eftilagimod Alpha and IMP761 for the Quarter Ended 31 March 2024 CI
Canaccord Starts Immutep at Buy, Price Target is AU$1.00 MT
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Phase IIb Trial Evaluating Efti in Combination With KEYTRUDA in First Line Metastatic Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression CI
Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck MT
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B CI
Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761 CI
Immutep Taps Center for Human Drug Research for IMP761 Human Clinical Trial MT
Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer CI
Australian Shares Tick Down as US Fed Chair Flags Likely Rate Cut Delay MT
Immutep Obtains Support from Spanish Health Agency for Efti Registrational Trial MT
More news
1 week-4.35%
Current month+2.33%
1 month+2.33%
3 months+25.71%
6 months+49.15%
Current year+27.54%
More quotes
1 week
Extreme 0.43
1 month
Extreme 0.405
Current year
Extreme 0.325
1 year
Extreme 0.26
3 years
Extreme 0.225
5 years
Extreme 0.1
10 years
Extreme 0.1
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 31/12/10
Director of Finance/CFO - 28/02/18
Chief Tech/Sci/R&D Officer - 30/04/23
Members of the board TitleAgeSince
Chairman 74 07/05/13
Chief Executive Officer 51 31/12/10
Director/Board Member - 02-13
More insiders
Date Price Change Volume
30/05/24 0.44 0.00% 2 081 315
29/05/24 0.44 0.00% 418,498
28/05/24 0.44 -2.22% 1,162,891
27/05/24 0.45 +1.12% 968,327
24/05/24 0.445 -3.26% 859,103

Delayed Quote Australian S.E., May 30, 2024 at 07:10 am

More quotes
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
0.44 AUD
Average target price
0.978 AUD
Spread / Average Target